Antitoxin reduces botulinum side effects.
Scott
A B
AB
Smith-Kettlewell Eye Research Foundation, San Francisco, California.
D001763:Blepharoptosis / Q000517:prevention & control; D001764:Blepharospasm / Q000503:physiopathology / Q000628:therapy*; D001904:Botulinum Antitoxin / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000037:antagonists & inhibitors*; D004305:Dose-Response Relationship, Drug; D005141:Eyelid Diseases / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009801:Oculomotor Muscles / Q000187:drug effects / Q000503:physiopathology; D009886:Ophthalmoplegia / Q000139:chemically induced / Q000517:prevention & control; D013035:Spasm / Q000628:therapy; D013285:Strabismus / Q000628:therapy; D013563:Sympathectomy, Chemical / Q000009:adverse effects*
D001904:Botulinum Antitoxin; D001905:Botulinum Toxins